Articles from General Atomics

General Atomics announced today a $20 million, ten-year strategic investment in Fusion Fuel Cycles, Inc. (FFC), a Canadian joint venture between Canadian Nuclear Laboratories (CNL) and Kyoto Fusioneering. This landmark collaboration will accelerate the development of UNITY-2, a cutting-edge tritium fuel cycle test facility poised to play a pivotal role in clearing the path towards commercializing fusion energy.

Expanding Collaboration Accelerates Path to Clean, Sustainable Fusion Energy

Collaboration to Strengthen California’s Leadership in Fusion Energy Innovation

Funding Will Drive Target Fabrication and Laser Study for Commercial Inertial Fusion Power Plants and Support Critical Systems Research for Magnetic Fusion Energy

Renewed Agreement with National Nuclear Security Administration Provides Cutting-Edge Components for U.S. Nuclear Stockpile Stewardship Program

Leading U.S. fusion facility reaches 200,000 experimental “shots”

New Open-Source Software Aims to Drive Fusion Innovation for a Clean Energy Future

GA team wins R&D 100 Professional Award for developing history-making technologies that support fusion ignition

Experiments at DIII-D National Fusion Facility achieve critical combination of plasma confinement and density required by many fusion power plant designs

GA-developed characterization system dramatically improves high-quality target selection; facilitates at least five instances of fusion ignition

GA to team with Lawrence Livermore National Laboratory on the STARFIRE hub and Colorado State University on the RISE hub to advance inertial fusion energy research

Companies to cooperate on HTS technologies for fusion energy and other applications

SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Diazyme Laboratories, Inc. received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration on December 6, 2022, for use of the Diazyme SARS-CoV-2 Neutralizing Antibody CLIA Kit. The test is a high throughput, fully automated assay for the qualitative detection of SARS-CoV-2 neutralizing antibodies and can produce results in 35 minutes. The assay is run on the DZ-Lite 3000 Plus, Diazyme’s FDA-cleared automated analyzer.